What is the medication for overactive bladder?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 2, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The most effective medication for overactive bladder is mirabegron (Myrbetriq), a beta-3 adrenergic agonist, which works by relaxing the bladder muscle, typically started at 25mg daily, as recommended by the latest guidelines 1. When treating overactive bladder, several medications are available, including anticholinergics such as oxybutynin (Ditropan), tolterodine (Detrol), solifenacin (VESIcare), darifenacin (Enablex), fesoterodine (Toviaz), and trospium chloride (Sanctura) 1.

  • Typical starting doses for anticholinergics are low, such as oxybutynin 5mg twice daily or tolterodine 2mg twice daily, with adjustments based on response and side effects.
  • Another effective option is mirabegron (Myrbetriq), which works differently by relaxing the bladder muscle, typically started at 25mg daily.
  • These medications work by blocking the nerve signals that trigger bladder contractions, reducing urgency, frequency, and urge incontinence.
  • Common side effects of anticholinergics include dry mouth, constipation, and blurred vision, while mirabegron may cause high blood pressure.
  • Treatment typically continues long-term as symptoms often return when medication is stopped.
  • Patients should also consider lifestyle modifications like fluid management, bladder training, and pelvic floor exercises alongside medication for optimal results, as outlined in the latest guidelines 1.
  • The American Urological Association (AUA) and the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) recommend a stepwise approach to treatment, starting with lifestyle modifications and behavioral therapies, followed by pharmacologic therapies, and finally minimally invasive and invasive therapies if necessary 1.

From the FDA Drug Label

Mirabegron extended-release tablets are indicated for the treatment of OAB in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency. Tolterodine tartrate tablets are a prescription medicine for adults used to treat the following symptoms due to a condition called overactive bladder: • Urge urinary incontinence: a strong need to urinate with leaking or wetting accidents • Urgency: a strong need to urinate right away • Frequency: urinating often

The medications for overactive bladder are:

  • Mirabegron (2, 2)
  • Tolterodine (3)

From the Research

Medications for Overactive Bladder

The medications for overactive bladder can be categorized into several types, including:

  • Antimuscarinic medications, such as oxybutynin 4, tolterodine 5, and trospium 6, which work by blocking the binding of acetylcholine to muscarinic receptors in the bladder
  • β3-adrenergic agonists, such as vibegron 7, which increase the capacity of the bladder and reduce the number of daily micturitions and nocturia
  • Other medications, such as solifenacin and darifenacin 6, which are more selective for the bladder than older agents and have been shown to improve quality of life in women with overactive bladder and urinary incontinence

Comparison of Medications

Studies have compared the efficacy and tolerability of different medications for overactive bladder, including:

  • A study that found tolterodine to be as effective as oxybutynin, but better tolerated 5
  • A study that found solifenacin to produce a somewhat greater decrease in the number of incontinence episodes than extended-release tolterodine, with no difference in tolerability 6
  • A study that found newer agents, such as trospium, solifenacin, and darifenacin, to be at least as effective as their predecessors, although it is unclear whether they are better tolerated 6

New Treatment Options

Researchers are also investigating new treatment options for overactive bladder, including:

  • Vanilloid receptor agonists, tachykinin receptor antagonists, potassium channel openers, and beta(3)-adrenoceptor agonists 8
  • New pharmaceutical formulations, such as extended release formulations of oxybutynin and tolterodine, which have demonstrated improved tolerability in clinical studies 8

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.